From The New York Times:
A new drug hailed last year as a breakthrough for black heart patients has become a major disappointment for its maker, NitroMed, and the company announced yesterday that two top executives involved in bringing the product to market had resigned...Technorati Tags: nitromed, bidil, hydralazine, nitroglycerine, drugs, new york times
The American Heart Association officially designated BiDil as a major treatment advance after research indicated it could extend the lives of black heart-failure patients by 43 percent over 18 months. And some financial analysts had predicted annual sales could eventually reach $825 million, based on BiDil's use by about 750,000 black heart failure patients...
The company also was criticized for pricing the drug at $1.80 a pill, about twice what some financial analysts had predicted. Some patients take up to six pills a day.
Post a Comment